Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nurix Therapeutics, Inc.NRIX · Entity 1156 | Director | May 15, 2026 | May 15, 2026 |
| Rapport Therapeutics, Inc.RAPP · Entity 4394 | Director | June 10, 2026 | June 10, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | SVP & Chief Accounting Officer | February 26, 2021 | March 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nurix Therapeutics, Inc.
Report date May 15, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.86 · Expires 2036-05-14 | Direct | 31,250 |
Reported balance
After 2026-05-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-15 · Grant · Acquired 31,250 · Balance 31,250 F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.
Rapport Therapeutics, Inc.
Report date June 10, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.21 · Expires 2036-06-10 | Direct | 15,200 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 15,200 · Balance 15,200 F1: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.
VERTEX PHARMACEUTICALS INC / MA
Report date February 26, 2021 · Filed March 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,884 |
Ending reported balance
After 2021-03-01 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2021-02-26 · Tax withholding · Disposed 2,218 · Balance 12,666 Row 2 · 2021-03-01 · Sale · Disposed 1,026 · Balance 11,640 F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2: Open market sales reported on this line occurred at a weighted average price of $210.13 (range $209.93 to $210.77). F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Row 3 · 2021-03-01 · Sale · Disposed 610 · Balance 11,030 F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4: Open market sales reported on this line occurred at a weighted average price of $211.45 (range $210.96 to $211.95). Row 4 · 2021-03-01 · Sale · Disposed 915 · Balance 10,115 F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5: Open market sales reported on this line occurred at a weighted average price of $212.51 (range $211.96 to $212.85). Row 5 · 2021-03-01 · Sale · Disposed 231 · Balance 9,884 F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6: Open market sales reported on this line occurred at a weighted average price of $213.12 (range $212.96 to $213.27). |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 169 |
Reported balance
Holding disclosure · report date 2021-02-26 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 169 |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $210.13 (range $209.93 to $210.77).
F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $211.45 (range $210.96 to $211.95).
F5: Open market sales reported on this line occurred at a weighted average price of $212.51 (range $211.96 to $212.85).
F6: Open market sales reported on this line occurred at a weighted average price of $213.12 (range $212.96 to $213.27).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 11, 2019 Filed Feb 13, 2019 21:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,100 | $180.38 | $378,798.00 |
DisclosureSEC source: 0001209191-19-009630 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,286 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $179.35 (range $178.75 to $179.64). F4 · price: Open market sales reported on this line occurred at a weighted average price of $180.38 (range $179.78 to $180.76). Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 21:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,400 | $179.35 | $251,090.00 |
DisclosureSEC source: 0001209191-19-009630 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,386 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $179.35 (range $178.75 to $179.64). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 06, 2019 Filed Feb 7, 2019 21:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,289 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-19-008045 · doc4.xml · derivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,157 Underlying: Common Stock · 1,289 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/02/2016. Read SEC document |
| February 06, 2019 Filed Feb 7, 2019 21:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,289 | $193.00 | $248,777.00 |
DisclosureSEC source: 0001209191-19-008045 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,649 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 06, 2019 Filed Feb 7, 2019 21:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,289 | $91.05 | $117,363.45 |
DisclosureSEC source: 0001209191-19-008045 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 7,449 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0001209191-19-008588 · doc4.xml · derivative · entry 5 Silva Paul M · CIK 0001446372 · SVP & Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,449 Underlying: Common Stock · 7,449 shares Expires 2029-02-05 F4 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/6/2019. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008588 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,786 F3 · shares: Restricted stock unit award that vests on 2/28/2021. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 2,917 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008588 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,786 F2 · shares: Restricted stock unit award that vests in installments beginning on 2/24/2020. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 4,220 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008588 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,869 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 2/3/2018 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/6/2019. The earned performance shares will vest in installments beginning on 2/17/2019. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 809 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-19-007770 · doc4.xml · derivative · entry 7 Silva Paul M · CIK 0001446372 · SVP & Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,472 Underlying: Common Stock · 809 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2017. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 120 | $188.33 | $22,599.60 |
DisclosureSEC source: 0001209191-19-007770 · doc4.xml · nonDerivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,649 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $188.33 (range $188.25 to $188.35). Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,268 | $186.85 | $423,775.80 |
DisclosureSEC source: 0001209191-19-007770 · doc4.xml · nonDerivative · entry 5 Silva Paul M · CIK 0001446372 · SVP & Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,769 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $186.85 (range $186.62 to $187.33). Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 450 | $186.17 | $83,776.50 |
DisclosureSEC source: 0001209191-19-007770 · doc4.xml · nonDerivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,037 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $186.17 (range $185.74 to $186.52). Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 600 | $185.11 | $111,066.00 |
DisclosureSEC source: 0001209191-19-007770 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,487 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $185.11 (range $184.54 to $185.49). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 809 | $189.19 | $153,054.71 |
DisclosureSEC source: 0001209191-19-007770 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,087 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 809 | $86.52 | $69,994.68 |
DisclosureSEC source: 0001209191-19-007770 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,896 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 17, 2019 Filed Jan 18, 2019 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 859 | $0.00 Strike: $90.29 | $0.00 |
DisclosureSEC source: 0001209191-19-004552 · doc4.xml · derivative · entry 10 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,157 Underlying: Common Stock · 859 shares Expires 2026-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/12/2016. Read SEC document |
| January 17, 2019 Filed Jan 18, 2019 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 859 | $0.00 Strike: $90.29 | $0.00 |
DisclosureSEC source: 0001209191-19-004552 · doc4.xml · derivative · entry 9 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,016 Underlying: Common Stock · 859 shares Expires 2026-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/12/2016. Read SEC document |
| January 17, 2019 Filed Jan 18, 2019 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,289 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-19-004552 · doc4.xml · derivative · entry 8 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,446 Underlying: Common Stock · 1,289 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/02/2016. Read SEC document |
| January 17, 2019 Filed Jan 18, 2019 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 859 | $190.29 | $163,459.11 |
DisclosureSEC source: 0001209191-19-004552 · doc4.xml · nonDerivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,087 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| January 17, 2019 Filed Jan 18, 2019 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 859 | $90.29 | $77,559.11 |
DisclosureSEC source: 0001209191-19-004552 · doc4.xml · nonDerivative · entry 5 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,946 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 17, 2019 Filed Jan 18, 2019 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 859 | $190.29 | $163,459.11 |
DisclosureSEC source: 0001209191-19-004552 · doc4.xml · nonDerivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,087 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| January 17, 2019 Filed Jan 18, 2019 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 859 | $90.29 | $77,559.11 |
DisclosureSEC source: 0001209191-19-004552 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,946 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 17, 2019 Filed Jan 18, 2019 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,289 | $191.05 | $246,263.45 |
DisclosureSEC source: 0001209191-19-004552 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,087 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| January 17, 2019 Filed Jan 18, 2019 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,289 | $91.05 | $117,363.45 |
DisclosureSEC source: 0001209191-19-004552 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,376 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2018 Filed Dec 4, 2018 21:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 809 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-18-060817 · doc4.xml · derivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,281 Underlying: Common Stock · 809 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2017. Read SEC document |
| December 03, 2018 Filed Dec 4, 2018 21:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 809 | $186.52 | $150,894.68 |
DisclosureSEC source: 0001209191-18-060817 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,087 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| December 03, 2018 Filed Dec 4, 2018 21:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 809 | $86.52 | $69,994.68 |
DisclosureSEC source: 0001209191-18-060817 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,896 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 22:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 12 | $163.75 | $1,965.00 |
DisclosureSEC source: 0001209191-18-059275 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,087 F1 · kind: Transaction made pursuant to Mr. Silva's company-approved trading plan under Rule 10b5-1. Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 21:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 809 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-18-045582 · doc4.xml · derivative · entry 7 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,090 Underlying: Common Stock · 809 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/3/2017. Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 21:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 809 | $174.20 | $140,927.80 |
DisclosureSEC source: 0001209191-18-045582 · doc4.xml · nonDerivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,087 F1 · kind: Transaction made pursuant to Mr. Silva's company-approved trading plan under Rule 10b5-1. Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 21:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 809 | $86.52 | $69,994.68 |
DisclosureSEC source: 0001209191-18-045582 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,896 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2018 Filed Aug 6, 2018 21:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,289 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-18-045582 · doc4.xml · derivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,735 Underlying: Common Stock · 1,289 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/2/2016. Read SEC document |
| August 02, 2018 Filed Aug 6, 2018 21:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,289 | $174.59 | $225,046.51 |
DisclosureSEC source: 0001209191-18-045582 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,087 F1 · kind: Transaction made pursuant to Mr. Silva's company-approved trading plan under Rule 10b5-1. Read SEC document |
| August 02, 2018 Filed Aug 6, 2018 21:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,289 | $91.05 | $117,363.45 |
DisclosureSEC source: 0001209191-18-045582 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,376 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 16, 2018 Filed Jul 18, 2018 21:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 860 | $0.00 Strike: $96.87 | $0.00 |
DisclosureSEC source: 0001209191-18-043131 · doc4.xml · derivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 860 shares Expires 2024-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| July 16, 2018 Filed Jul 18, 2018 21:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 860 | $179.85 | $154,671.00 |
DisclosureSEC source: 0001209191-18-043131 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,087 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| July 16, 2018 Filed Jul 18, 2018 21:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 860 | $96.87 | $83,308.20 |
DisclosureSEC source: 0001209191-18-043131 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,947 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 12, 2018 Filed Jul 16, 2018 20:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 860 | $0.00 Strike: $90.29 | $0.00 |
DisclosureSEC source: 0001209191-18-042630 · doc4.xml · derivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,875 Underlying: Common Stock · 860 shares Expires 2026-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 7/12/2016. Read SEC document |
| July 12, 2018 Filed Jul 16, 2018 20:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 860 | $175.02 | $150,517.20 |
DisclosureSEC source: 0001209191-18-042630 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,087 F1 · kind: Transaction made pursuant to Mr. Silva's company-approved trading plan under Rule 10b5-1. Read SEC document |
| July 12, 2018 Filed Jul 16, 2018 20:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 860 | $90.29 | $77,649.40 |
DisclosureSEC source: 0001209191-18-042630 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,947 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 809 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-18-041006 · doc4.xml · derivative · entry 10 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,899 Underlying: Common Stock · 809 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2017. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,289 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-18-041006 · doc4.xml · derivative · entry 9 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,024 Underlying: Common Stock · 1,289 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/02/2016. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 859 | $0.00 Strike: $96.87 | $0.00 |
DisclosureSEC source: 0001209191-18-041006 · doc4.xml · derivative · entry 8 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 860 Underlying: Common Stock · 859 shares Expires 2024-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/15/2014. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 809 | $161.57 | $130,710.13 |
DisclosureSEC source: 0001209191-18-041006 · doc4.xml · nonDerivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,087 F1 · kind: Transaction made pursuant to Mr. Silva's company-approved trading plan under Rule 10b5-1. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 809 | $86.52 | $69,994.68 |
DisclosureSEC source: 0001209191-18-041006 · doc4.xml · nonDerivative · entry 5 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,896 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,289 | $166.05 | $214,038.45 |
DisclosureSEC source: 0001209191-18-041006 · doc4.xml · nonDerivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,087 F1 · kind: Transaction made pursuant to Mr. Silva's company-approved trading plan under Rule 10b5-1. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,289 | $91.05 | $117,363.45 |
DisclosureSEC source: 0001209191-18-041006 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,376 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 859 | $171.87 | $147,636.33 |
DisclosureSEC source: 0001209191-18-041006 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,087 F1 · kind: Transaction made pursuant to Mr. Silva's company-approved trading plan under Rule 10b5-1. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 859 | $96.87 | $83,211.33 |
DisclosureSEC source: 0001209191-18-041006 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,946 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.